Evidence map›Paper›PMID 30549245›Full record

ArticleJournal of the International AIDS Society2018

Persons living with HIV with advanced HIV disease: need for novel care models.

Chloe A Teasdale, Katharine Yuengling, Peter Preko, Maureen Syowai, Felix Ndagije, Miriam Rabkin, Elaine J Abrams, Wafaa M El-Sadr

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Implementation of Low-Barrier Human Immunodeficiency Virus Care: Lessons Learned From the Max Clinic in Seattle.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chloe A TeasdaleICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.ORCID 0000-0001-9165-8972
Katharine YuenglingICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.ORCID 0000-0002-4003-936X
Peter PrekoICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.
Maureen SyowaiICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.
Felix NdagijeICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.
Miriam RabkinICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.ORCID 0000-0002-2342-4362
Elaine J AbramsICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.
Wafaa M El-SadrICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY, USA.
Columbia University · US

Funding

RAPID EXP. OF ART FOR HIV-INFECTED PERSONS IN SELECTED COUNTRIES FOR PEPFARU62PS223540 · PS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EL-SADR, WAFAA M. · 2004 to 2011
$554.7M
TECHNICAL ASSISTANCE IN SUPPORT OF HIV PREVENTION, CARE AND TREATMENT PROGRAMSU2GPS001537 · PS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JUSTMAN, JESSICA · 2009 to 2014
$13.6M
NCHHSTP CDC HHS U2G PS001537NCHHSTP CDC HHS U62 PS223540PEPFAR
6 · The paper itself

Abstract

introductionDespite increasing focus on test and treat strategies for people living with HIV (PLHIV), many continue to enrol late in care and initiate antiretroviral therapy (ART) when they have advanced HIV disease.

methodsWe analyzed PLHIV ≥15 years of age starting ART in Ethiopia, Kenya, Mozambique and Tanzania from 2005 to 2015 based on CD4+ groups at ART initiation (≥200, 100 to 199, 50 to 99 and <50 cells/mm RESULTS AND DISCUSSION: A total of 305,443 PLHIV were included in the analysis: 118,580 (38.8%) CD4+ ≥200, 91,788 (30.1%) CD4+ 100 to 199, 44,029 (14.4%) CD4+ 50 to 99 and 51,046 (16.7%) CD4+ <50 cells/mm

conclusionsGreater efforts, including the identification of effective differentiated service delivery models, are needed to ensure that all PLHIV starting treatment can garner the benefits from ART and achieve favourable outcomes.

Indexed as

Time-to-TreatmentAdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountEthiopiaFemaleHIV InfectionsHumansKenyaLost to Follow-UpMaleMiddle AgedMozambiqueProportional Hazards ModelsAnti-HIV AgentsattritionCD4 cell countdifferentiated service delivery modelslate ART initiationloss to follow-upmortality

Identifiers

PMID30549245
PMCPMC6293147
OpenAlexW2903977051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.